Dublin, Nov. 05, 2024 (GLOBE NEWSWIRE) — The “Antibody Drug Conjugates (ADC) – Global Strategic Business Report” has been added to ResearchAndMarkets.com’s offering.
The global market for Antibody Drug Conjugates (ADC) was estimated at US$9.4 Billion in 2023 and is projected to reach US$23.2 Billion by 2030, growing at a CAGR of 13.8% from 2023 to 2030.
Antibody Drug Conjugates (ADCs) are a cutting-edge class of biopharmaceuticals designed to target and treat cancer with high precision. ADCs combine the targeting ability of monoclonal antibodies with potent cytotoxic drugs, enabling them to deliver chemotherapeutic agents directly to cancer cells while minimizing damage to healthy tissues. This targeted approach has made ADCs an increasingly attractive option in oncology, especially for cancers that have proven resistant to traditional treatments. By utilizing monoclonal antibodies that bind to specific proteins on the surface of cancer cells, ADCs can deliver toxic payloads more efficiently, enhancing therapeutic outcomes while reducing systemic side effects. ADCs are used in the treatment of various cancers, including breast cancer, lymphomas, and solid tumors.
How Is the ADC Market Segmented and What Are the Key Applications?
Technologically, the market is divided into types of linkers and payloads used, which are critical components in ensuring the drug’s stability and efficacy. In terms of application, breast cancer currently dominates the ADC market, given the high success rate of treatments like Kadcyla and Enhertu. Other target indications include hematologic malignancies and solid tumors, with ongoing clinical trials aiming to expand the use of ADCs to more cancer types.
End-users primarily include hospitals, oncology clinics, and cancer research institutes, where ADCs are administered as part of comprehensive cancer treatment regimens. North America leads the market due to its advanced healthcare infrastructure and high investment in oncology research, while Europe and Asia-Pacific are emerging as key regions due to increasing healthcare expenditures and cancer prevalence.
How Are Technological Innovations Impacting the ADC Market?
Technological advancements are playing a pivotal role in the growth and effectiveness of ADCs. Innovations in linker chemistry have improved the stability and precision of ADCs, enabling better drug release at the cancer site and reducing off-target toxicity. Advances in cytotoxic payloads are also enhancing the potency of ADCs, making them more effective against drug-resistant cancer cells.
Moreover, ongoing research in identifying new cancer biomarkers is expanding the potential applications of ADCs beyond current use cases, allowing for the development of next-generation ADCs that target previously untreatable cancers. Regulatory agencies like the FDA are also expediting approvals for new ADC therapies, recognizing their potential to transform cancer treatment.
What Factors Are Driving the Growth in the Antibody Drug Conjugates Market?
The growth in the Antibody Drug Conjugates (ADC) market is driven by several factors, including the increasing prevalence of cancer and the demand for more targeted, effective treatments. The advancements in linker technologies and payload delivery systems have enhanced the efficacy and safety profile of ADCs, contributing to their growing adoption in oncology. Furthermore, the rise in personalized medicine, where treatments are tailored to individual patients based on genetic and molecular markers, is propelling the development of ADCs. Clinical success and the approval of leading ADC products have spurred further investment in R&D, expanding the pipeline for future ADC therapies. Additionally, growing awareness and demand for therapies with fewer side effects compared to traditional chemotherapy are further driving market growth.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Breast Cancer End-Use segment, which is expected to reach US$11 Billion by 2030 with a CAGR of a 14.5%. The Blood Cancer End-Use segment is also set to grow at 13.4% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, which was estimated at $2.6 Billion in 2023, and China, forecasted to grow at an impressive 18.5% CAGR to reach $5.2 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Key Questions Answered:
- How is the Global Antibody Drug Conjugates (ADC) Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of major players in the Antibody Drug Conjugates (ADC) market such as ADC Therapeutics SA, Astellas Pharma, Inc., AstraZeneca Plc, Daiichi Sankyo Co., Ltd., Enzo Biochem, Inc. and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 52 companies featured in this Antibody Drug Conjugates (ADC) market report include:
- ADC Therapeutics
- Astellas Pharma
- AstraZeneca
- Daiichi Sankyo Co.
- Enzo Biochem
- F. Hoffmann-La Roche
- Gilead Sciences
- GSK
- ImmunoGen
- MabPlex International
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 193 |
| Forecast Period | 2023 – 2030 |
| Estimated Market Value (USD) in 2023 | $9.4 Billion |
| Forecasted Market Value (USD) by 2030 | $23.2 Billion |
| Compound Annual Growth Rate | 13.8% |
| Regions Covered | Global |
Key Topics Covered:
MARKET OVERVIEW
- World Market Trajectories
- Antibody Drug Conjugates (ADC) – Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
FOCUS ON SELECT PLAYERS
- ADC Therapeutics
- Astellas Pharma
- AstraZeneca
- Daiichi Sankyo Co.
- Enzo Biochem
- F. Hoffmann-La Roche
- Gilead Sciences
- GSK
- ImmunoGen
- MabPlex International
MARKET TRENDS & DRIVERS
- Rising Prevalence of Cancer Drives Demand for Targeted Therapeutic Solutions
- Technological Advancements in Biopharmaceuticals Propel Growth of ADC Market
- Expansion of Precision Medicine Strengthens Business Case for Antibody Drug Conjugates
- Rising Focus on Immuno-Oncology Fuels Innovation in ADC Development
- Advancements in Targeted Drug Delivery Systems Propel Growth of ADC Therapies
- Expanding Use of ADCs in Hematologic Malignancies Drives Market Demand
- Rising Interest in Combination Therapies Strengthens Adoption of ADCs in Cancer Treatment
- Increasing Focus on Personalized Medicine Expands Addressable Market for ADC-Based Therapies
- Growing Awareness of Precision Therapeutics Sustains Demand for Targeted Cancer Therapies
- Advancements in Payload and Linker Technologies Generate Opportunities for Innovative ADC Products
- Rising Prevalence of Chronic Diseases Beyond Cancer Expands Applications of ADCs
For more information about this report visit https://www.researchandmarkets.com/r/gw470l
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Antibody Drug Conjugates (ADC) Market
